Mogamulizumab
- Generic Name
- Mogamulizumab
- Brand Names
- Poteligeo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1159266-37-1
- Unique Ingredient Identifier
- YI437801BE
- Background
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect th...
- Indication
Mogamulizumab is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
- Associated Conditions
- Refractory Mycosis Fungoides and Sezary Syndrome, Relapsed Mycosis Fungoides/Sezary Syndrome
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath